Published Sep 21, 2026, 7:43 AM ET · Updated 2 months ago · 1 source
RNA drug developer ADARx seeks $1.74 billion valuation in US IPO
reuters
·
Original Report
ADARx Pharmaceuticals is targeting a valuation of up to $1.74 billion in its US initial public offering, the company developing RNA drugs said on Monday.